Enanta Pharmaceuticals Inc (ENTA)

[Gene-e]

I suppose that, theoretically, fusion inhibitors should be better for prophylaxis and N-inhibitors for treatment. However, other properties such as potency, safety, and PK might be more important. It's likely that, as with HIV and HCV, a combination of compounds with different modes of action would have significant synergy."